Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2; no study information or eligibility details appear to be altered.SummaryDifference0.1%

- Check20 days agoChange DetectedThe funding and operating status banner was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedTimestamp-related label updates and new date references (e.g., 'Last Update Posted (Estimated)' and 2025-11 dates) were added; these adjustments do not modify the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedThe new screenshot shows an updated last update date and minor formatting adjustments; core study details appear unchanged.SummaryDifference0.5%

- Check63 days agoChange Detected- Added a government funding notice and operating status guidance, and added version 3.2.0. - Removed version 3.1.0.SummaryDifference4%

- Check71 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.